Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

Canadian Cancer Trials Group CXC.1 / GOG 0219

Canadian Cancer Trials Group CXC.1 / GOG 0219 -- A Phase III Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage 1B2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis -- was closed to accrual on 21 December 2009.

This trial had been temporarily suspended as of September 1, 2009 due to the shortage of the investigational agent Tirapazamine. Due to the continued inability of the Gynecologic Oncology Group to obtain supplies of Tirapazamine, the trial is now permanently closed to accrual with the official date of closure being considered to be 5:00 p.m. EST September 1, 2009.

For more information about the closure of this trial, please go to the trial website at http://www.ctg.queensu.ca/trials/gynecologic/cxc1/cxc1.html.


Canadian Cancer Trials Group HD.8 / EORTC 20012

Canadian Cancer Trials Group HD.8 / EORTC 20012 -- BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) versus ABVD (8 Cycles) in Stage III & IV Hodgkin's Lymphoma -- is closed to accrual as of Friday, January 8 at 3 pm EST.

This study reached its target accrual of 550 patients. Many thanks to all of those who contributed to the successful completion of this trial.

For more information about the closure of this trial, please go to the trial website at http://www.ctg.queensu.ca/trials/hematologic/hd8/hd8.html.